EUCTR2013-003640-23-GB进行中（未招募）1 期
Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS) - Proteus study
AIBILI - Association for Innovation and Biomedical Research on Light and Image0 个研究点目标入组 94 人开始时间: 2013年11月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.High-risk proliferative diabetic retinopathy (HR-PDR);
- •i. Neovascularization in the disc = 1/4 disc area OR Neovascularization Elsewhere = 1/2 disc area;
- •ii. Neovascularization Elsewhere < 1/2 disc area + vitreous and/or pre-retinal haemorrhage and/or rubeosis;
- •iii. Neovascularization in the disc <1/4 disc area + vitreous and/or pre-retinal haemorrhage and/or rubeosis;
- •2. Best-corrected visual acuity at baseline = 24 ETDRS letters score (approximate Snellen equivalent 20/320).
- •3. Type I or Type II diabetic subjects of either gender;
- •4. Age = 18 years;
- •5. Ability to provide written informed consent;
- •6. Ability to return for all clinical trial visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 47
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 47
排除标准
- •1. Any intraocular surgery within 6 months before trial enrolment, including:
- •a. Prior scatter (panretinal) or focal/grid photocoagulation;
- •b. Eyes who have received YAG laser, or peripheral retinal cryoablation, or laser retinopexy (for retinal tears only);
- •2. Fibrovascular proliferation with retinal traction;
- •3. Other cause of retinal Neovascularization (retinal vein occlusion, radiation retinopathy or others);
- •4. Atrophy/scarring/fibrosis/ hard exudates involving the centre of the macula;
- •5. Significant media opacities or inadequate pupillary dilation, which might interfere with visual acuity, assessment of toxicity or fundus photography;
- •6. Any likelihood that the subject will require cataract surgery within the following 1 year;
- •7. Diabetic macular edema with central involvement, i.e., central macular thickness (Central Point Thickness) > 300 µm (Stratus OCT) equivalent values measured by SD-OCT, adjusted according to the SD-OCT machine used;
- •8. Previous vitrectomy;
- •9. Intraocular pressure > 21 mmHg;
- •10. Previous anti-VEGF therapy within the last 3 months;
- •11. Previous treatment with periocular and/or intravitreal corticosteroids within the last 3 months;
- •12. Known serious allergies or history of hypersensitivity to fluorescein used in angiography, or to components of Lucentis® formulation;
- •13. Acute ocular or periocular infection;
- •14. Active severe ocular or periocular inflammation;
- •15. Previous filtering surgery (e.g., trabeculectomy) or placement of a glaucoma drainage device (e.g., tube-shunt surgery).
- •16. Systolic BP > 170 mmHg or diastolic BP > 100 mmHg;
- •17. HbA1C level >11% or recent signs of uncontrolled diabetes;
- •18. Any of the following underlying systemic diseases:
- •a. History or evidence of severe cardiac disease, e.g. NYHA Functional Class III or IV, clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction, or revascularization procedure within 6 months prior to baseline, or ventricular tachyarrhythmia requiring treatment;
- •b. History or evidence of clinically significant peripheral vascular disease such as intermittent claudication or prior amputation;
- •c. Renal failure requiring dialysis or renal transplant or renal insufficiency with creatinine levels > 2.0 mg/dl at screening;
- •d. Stroke (within 12 months of trial entry);
- •e. Any major surgical procedure within one month before trial enrolment;
- •19. Subject with a condition (such as advanced, severe or unstable disease or its treatment) or is in a situation which may put him/her at significant risk, which may confound the study results or may interfere significantly with the subject’s participation in the study;
- •20. Previous radiation to the head in the region of the study eye;
- •21. Use of any other investigational drugs within the last 3 months (for Diabetic Retinopathy or other condition);
- •22. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases;
- •23. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation.
- •24. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant UNLESS they are: using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly,
研究者
相似试验
进行中（未招募）
1 期
Prospective, randomized, multicenter, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS)EUCTR2013-003640-23-PTAIBILI - Association for Innovation and Biomedical Research on Light and Image94
尚未招募
不适用
Study to compare the safety, tolerability and effectiveness of topical Minoxidil 5% solution in Indian male patients with mild to moderate pattern hair lossCTRI/2021/09/036777Hairrevive Centre for Hair Restoration Skin Rejuvenation
已完成
2 期
A open label, active control, phase 2 clinical study to evaluate immunogenicity, safety and tolerability of single heterologous booster dose of Protein Subunit Vaccine against SARS-CoV-2 Virus.CTRI/2023/09/057398Reliance Life Sciences Pvt Ltd RLS200
尚未招募
2 期
Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.SARS-CoV-2PACTR202307772264605RELIANCE LIFE SCIENCE1,550
终止
2 期
Stroke Self-Management Rehabilitation Trial (SMART)self-managementrehabilitationStroke - IschaemicStroke - HaemorrhagicstrokeACTRN12612001287820ational Institute for Stroke & Applied Neurosciences, AUT University700